Since cellular immunity is commonly suppressed in HNSCC patients, the administration of IL-2 leads to improved anti-tumoral immunity in vitro as well as in vivo, but this might cause severe side effects [24]. This evidence concerns the gene IL2 and head and neck squamous cell carcinoma.